Fees are a weakness here. The strategy's lofty fees are a high hurdle to clear, as it is priced within the most expensive quintile among peers.
AlphaCentric LifeSci Healthcare A LYFAX Fund Analysis
Morningstar’s Analysis LYFAX
Will LYFAX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar